Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in people with atopic dermatitis.
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the interleukin-13 is involved in inflammation and itch in atopic dermatitis by increasing the neuronal sensitivity to pruritogens.
However, the physiological mechanisms by which IL-13 increases the itch sensitivity are unclear. The aim of this project is to use, for the first time in humans, the monoclonal antibody Lebrikizumab that inhibits IL-13 with high affinity as a novel experimental tool to modulate the IL-13 pathway and evaluate its role in the transmission and processing of itch and pain.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lebrikizumab | Experimental | The initial doses will be subcutaneous Lebrikizumab 500 mg (two 250 mg injections) at both week 0 (baseline) and week 2, followed by 250 mg administered subcutaneously at week 4. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| histamine dihydrochloride | Other | A small drop of histamine dihydrochloride (1%, in saline) will be applied to two previously determined areas followed by a prick through the drop. |
| Measure | Description | Time Frame |
|---|---|---|
| Measuring itch by computerized Visual Analog Scale Scoring | The subjects will be asked to rate the sensation of itch on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no itch" and 100 indicates "worst itch imaginable". | Day 1 |
| Superficial blood perfusion | Superficial blood perfusion (SBP) is measured by a Speckle contrast imager | Day 1 |
| Wheal reaction | Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. | Day 1 |
| Average pruritis and pain numerical rating scale (NRS) | The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. | Day 1 |
| Skin peak pain numerical rating scale (SPP-NRS) | According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11- point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) | Day 1 |
| Peak pruritus numerical rating scale (PP-NRS) | The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) | Day 1 |
| Eczema Area and Severity Index (EASI) |
| Measure | Description | Time Frame |
|---|---|---|
| Mechanical Pain Thresholds (MPT) | This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. | Day 1 |
| Mechanical Pain Sensitivity (MPS) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Pregnancy or lactation
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark | Gistrup | 9260 | Denmark |
Not provided
| ID | Term |
|---|---|
| D011537 | Pruritus |
| ID | Term |
|---|---|
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D006632 | Histamine |
| ID | Term |
|---|---|
| D015306 | Biogenic Monoamines |
| D001679 | Biogenic Amines |
| D000588 | Amines |
| D009930 | Organic Chemicals |
Not provided
Not provided
Each participant will be treated with Lebrikizumab and will receive 2 pruritogens:
Histamine and cowhage
Not provided
Not provided
Not provided
Not provided
| Cowhage | Other | Approximately 30-35 cowhage spicules will be manually inserted into the subject's skin. |
|
This scale is used for patients with AD to assess severity and extent of the disease. The investigator/physician will assign scores based on redness, scratching, thickness, lichenification and percentage of affected body regions |
| Day 1 |
| Dermatology Life Quality Index (DLQI) | This questionnaire is a simple 10-question validated questionnaire that measures the impact of the skin disease on several aspects of the patient's life over the past week. The DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. | Day 1 |
| Itch Severity Scale (ISS) | This is a seven items questionnaire: itch description, frequency, effect on sleep, effect on mood, effect on sexual desire/function, itch intensity using Likert scale and body surface area involved | Day 1 |
| Patient Oriented Eczema Measure (POEM) | POEM is a questionnaire used for patients' self-monitoring of AD severity. It asks about the frequency of seven symptoms (itch, sleep disturbance, dryness, flaking, weeping, or oozing, bleeding, and cracking) in the past seven days, and the patient has to choose between these answers: No days, 1-2 days, 3-4 days, 5-6 days, Every day | Day 1 |
| Mechanically evoked itch (MEI) | MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). | Day 1 |
| Mechanically evoked itch (MEI) | MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). | Day 3 |
| Measuring pain by computerized Visual Analog Scale Scoring | The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". | Day 3 |
| Measuring pain by computerized Visual Analog Scale Scoring | The subjects will be asked to rate the sensation of pain on a 100 mm VAS scale ranging from 0 to 100 where 0 indicates "no pain" and 100 indicates "worst pain imaginable". | Day 4 |
| Superficial blood perfusion | Superficial blood perfusion (SBP) is measured by a Speckle contrast imager | Day 3 |
| Superficial blood perfusion | Superficial blood perfusion (SBP) is measured by a Speckle contrast imager | Day 4 |
| Wheal reaction | Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. | Day 3 |
| Wheal reaction | Wheal reaction measurement will be conducted immediately after the removal of pruritogens by measuring the longest diameter with a ruler. | Day 4 |
| Average pruritis and pain numerical rating scale (NRS) | The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. | Day 3 |
| Average pruritis and pain numerical rating scale (NRS) | The subject will be asked to retrospectively rate the average and worst itch/pain on an 11-point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain)experience they had during the last 7 days. | Day 4 |
| Skin peak pain numerical rating scale (SPP-NRS) | According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11- point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) | Day 3 |
| Skin peak pain numerical rating scale (SPP-NRS) | According to the SPP-NRS, the subject will be asked about "worst skin pain" they felt in the past 24 hours on an 11- point scale ranging from 0 to 10 (0 = no pain and 10 = worst imaginable pain) | Day 4 |
| Peak pruritus numerical rating scale (PP-NRS) | The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) | Day 3 |
| Peak pruritus numerical rating scale (PP-NRS) | The subject will be asked about the "worst itch" they felt in the past 24 hours on an 11-point scale ranging from 0 to 10 (0 = no itch and 10 = worst imaginable itch) | Day 4 |
| Eczema Area and Severity Index (EASI) | This scale is used for patients with AD to assess severity and extent of the disease. The investigator/physician will assign scores based on redness, scratching, thickness, lichenification and percentage of affected body regions | Day 3 |
| Eczema Area and Severity Index (EASI) | This scale is used for patients with AD to assess severity and extent of the disease. The investigator/physician will assign scores based on redness, scratching, thickness, lichenification and percentage of affected body regions | Day 4 |
| Dermatology Life Quality Index (DLQI) | This questionnaire is a simple 10-question validated questionnaire that measures the impact of the skin disease on several aspects of the patient's life over the past week. The DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. | Day 3 |
| Dermatology Life Quality Index (DLQI) | This questionnaire is a simple 10-question validated questionnaire that measures the impact of the skin disease on several aspects of the patient's life over the past week. The DLQI sum score is calculated by summing up the score of each item. Questions are scored on a four-point Likert scale: 0, not at all/not relevant; 1, a little; 2, a lot; and 3, very much. | Day 4 |
| Itch Severity Scale (ISS) | This is a seven items questionnaire: itch description, frequency, effect on sleep, effect on mood, effect on sexual desire/function, itch intensity using Likert scale and body surface area involved | Day 3 |
| Itch Severity Scale (ISS) | This is a seven items questionnaire: itch description, frequency, effect on sleep, effect on mood, effect on sexual desire/function, itch intensity using Likert scale and body surface area involved | Day 4 |
| Patient Oriented Eczema Measure (POEM) | POEM is a questionnaire used for patients' self-monitoring of AD severity. It asks about the frequency of seven symptoms (itch, sleep disturbance, dryness, flaking, weeping, or oozing, bleeding, and cracking) in the past seven days, and the patient has to choose between these answers: No days, 1-2 days, 3-4 days, 5-6 days, Every day | Day 3 |
| Patient Oriented Eczema Measure (POEM) | POEM is a questionnaire used for patients' self-monitoring of AD severity. It asks about the frequency of seven symptoms (itch, sleep disturbance, dryness, flaking, weeping, or oozing, bleeding, and cracking) in the past seven days, and the patient has to choose between these answers: No days, 1-2 days, 3-4 days, 5-6 days, Every day | Day 4 |
| Mechanically evoked itch (MEI) | MEI is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force). | Day 4 |
This test is conducted with the same pinprick set used to test the MPT. |
| Day 1 |
| Pressure Pain Thresholds (PPT) | Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. | Day 1 |
| Cold Detection Thresholds (CDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 1 |
| Warm Detection Thresholds (WDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 1 |
| Cold Pain Thresholds (CPT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 1 |
| Pain to Supra-threshold Heat Stimuli (STHS) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 1 |
| Mechanical Pain Thresholds (MPT) | This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. | Day 3 |
| Mechanical Pain Thresholds (MPT) | This test is conducted using a pinprick set. The set consists of 7 needles each with a diameter of 0.6 mm and different force applications: 8, 16, 32, 64, 128, 256, and 512 mN. | Day 4 |
| Mechanical Pain Sensitivity (MPS) | This test is conducted with the same pinprick set used to test the MPT. | Day 3 |
| Mechanical Pain Sensitivity (MPS) | This test is conducted with the same pinprick set used to test the MPT. | Day 4 |
| Pressure Pain Thresholds (PPT) | Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. | Day 3 |
| Pressure Pain Thresholds (PPT) | Pressure will be applied by a handheld electronic pressure algometer (Somedic AB, Stockholm, Sweden) on to the supinator muscle on the left forearm. | Day 4 |
| Cold Detection Thresholds (CDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 3 |
| Heat Pain Thrteshold | Day 1 |
| Cold Detection Thresholds (CDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 4 |
| Warm Detection Thresholds (WDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 3 |
| Warm Detection Thresholds (WDT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 4 |
| Heat Pain Thrteshold | Day 3 |
| Heat Pain Thrteshold | Day 4 |
| Pain to Supra-threshold Heat Stimuli (STHS) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 4 |
| Cold Pain Thresholds (CPT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 3 |
| Cold Pain Thresholds (CPT) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 4 |
| Pain to Supra-threshold Heat Stimuli (STHS) | The tests of thermal sensation will all be conducted using a TSA2 (Medoc Ltd, Israel) thermal sensory testing device | Day 3 |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D005021 |
| Ethylamines |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D012898 | Autacoids |
| D018836 | Inflammation Mediators |
| D001685 | Biological Factors |